Circulating parasite antigen in patients with hydrocephalus secondary to neurocysticercosis

American Journal of Tropical Medicine and Hygiene

Volumn 66, Issue 4, 2002, Pages 427-430

  Garcia, Hector H ^a   Gonzalez, A E ^a   Gilman, R H ^a   Bernal, T ^a   Rodriguez, S ^a   Pretell, E J ^a   Azcurra, O ^a   Parkhouse, R M E ^a   Tsang, V C W ^a   Harrison, L J S ^a   Martinez, S M ^a   Montano, S ^a   Martinez, J M ^a   Saavedra, H ^a   Verastegui, M ^a   Herrera, G ^a   Gavidia, C ^a   Falcon, N ^a   Evans, C A W ^a  

^a INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; PARASITE ANTIGEN;

ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BRAIN CALCIFICATION; CHRONIC INFLAMMATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYDROCEPHALUS; INTRACRANIAL HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUROCYSTICERCOSIS; WESTERN BLOTTING;

CESTODA;

EID: 0036330095     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.66.427     Document Type: Article

References (34)

1. Immigrants, imaging and immunoblots: The emergence of neurocysticercosis as a significant public health problem
2. Neurocysticercosis: A major cause of neurological disease worldwide
3. Taenia solium cysticercosis: Host-parasite interactions and the immune response
4. Neurocysticercosis: A new classification based on active and inactive forms. A study of 753 cases
5. Neurocysticercosis in epileptic persons in Medellin, Colombia
6. Neurocysticercosis: An update
7. A prognostic classification of cerebral cysticercosis: Therapeutic implications
8. Hydrocephalus in cerebral cysticercosis. Pathogenic and therapeutic considerations
9. Extraparenchymal neurocysticercosis: Report of five cases and review of management
10. Hydrocephalus secondary to cysticercotic arachnoiditis: A long-term follow-up review of 92 cases
11. A specific antigendetection ELISA for the diagnosis of human neurocysticercosis
12. Human neurocysticercosis: Comparison of enzyme immunoassay capture techniques based on monoclonal and polyclonal antibodies for the detection of parasite products in cerebrospinal fluid
13. Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients
14. Albendazole therapy for neurocysticercosis: A prospective double blind trial comparing 7 vs. 14 days of treatment
15. Prevalence of taeniosis among neurocysticercosis patients is related to the severity of cerebral infection
16. Enzyme-linked immunoelectrotransferency blot assay and glycoprotein antigens for diagnosing human cysticercosis (T. solium)
17. Serological evolution of neurocysticercosis patients after antiparasitic therapy
18. Specific detection of circulating surface/secreted glycoproteins of viable cysticerci in Taenia saginata cysticercosis
19. Magnitude of the disease burden from neurocysticercosis in a developing country
20. Mechanisms of hydrocephalus in cerebral cysticercosis: Implications for therapy
21. Neurocysticercosis: Focus on intraventricular disease
22. Discrepancies between cerebral computed tomography and Western blot in the diagnosis of neurocysticercosis
23. MR imaging in neurocysticercosis: A study of 56 cases
24. Cysticercus cellulosae - Its radiographic detection in the musculature and the central nervous system
25. Edema associated with calcified lesions in neurocysticercosis
26. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis
27. T. solium taeniasis/cysticercosis
28. Therapy for neurocysticercosis: A reappraisal
29. Therapy for neurocysticercosis: Comparison between albendazole and praziquantel
30. Albendazole therapy for subarachnoid and ventricular cysticercosis
31. Albendazole therapy for giant subarachnoid cysticerci
32. Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle
33. Controversies in the management of cysticercosis